AXCELON BIOPOLYMERS CORP. ANNOUNCES CLOSING OF PRIVATE PLACEMENT FINANCING IN ITS WOUNDCARE SUBSIDIARY
July 25, 2014
AXCELON BIOPOLYMERS CORP. ANNOUNCES CLOSING OF PRIVATE PLACEMENT FINANCING IN ITS WOUNDCARE SUBSIDIARY
November 25, 2014

AXCELON BIOPOLYMERS CORP. ANNOUNCES HEALTH CANADA LICENSE FOR ITS LEAD WOUNDCARE PRODUCT NANODERM©

London, Ontario, July 25th, 2014. Axcelon Biopolymers Corp., a biomaterials company developing biocellulose based products for woundcare, cardiovascular and other non-medical applications announced that the Canadian Health Protection Branch has granted a medical device Class 2 license for its flagship product Nanoderm©.

Nanoderm© is a unique woundcare product indicated for a variety of treatments including burns, dermabrasions as well as acute and chronic wounds. In most cases, it is a one-time application as the product provides a suitable barrier to infections while allowing gaseous exchange and pain alleviation. “We expect Nanoderm© to play a crucial role in the cost effective treatment of severe wounds which are a huge economic burden to the healthcare system in Canada”, said Dr.Chandra Panchal, CEO of Axcelon.   “The HPB License also allows us to move aggressively to get registrations in other world jurisdictions”, he added.

Nanoderm© will be manufactured in Canada by Axcelon’s partner ZBX Corporation of Toronto under ISO 13485 standards.

About Axcelon Biopolymers Corp.

Axcelon is a private company developing bacterial cellulose based products for biomedical devices as well as for non-medical applications. The company has several proprietary assets for development of advanced woundcare products, cardiovascular grafts, tympanic membrane as well as other high value consumer products. With head office in London, Ontario, the company has activities in Toronto as well as Montreal, Quebec.

Contact information:  Dr. Chandra Panchal, CEO; cpanchal@axcelonbp.com

Tel: 519 878 6157

www.axcelonbp.com

This news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks.